Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia (Q38813978)

6 September 2017

title

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia (English)

1 reference

6 September 2017

Ajoy Dias

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

4 June 2020

Gustavo F Westin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

4 June 2020

publication date

21 April 2016

1 reference

Current hematologic malignancy reports

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

4 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

4 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

253-264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27101015 AND SRC:MED&resulttype=core&format=json

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph ) acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

CD19 CAR Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

The molecular basis of T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-016-0326-1

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

21 January 2018

1 reference

12 December 2020

Venocclusive disease of the liver after allogeneic bone marrow transplantation in man

1 reference

12 December 2020

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

1 reference

12 December 2020

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

12 December 2020

Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia.

1 reference

12 December 2020

The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.

1 reference

12 December 2020

Acute lymphoblastic leukemia

1 reference

12 December 2020

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemi

1 reference

12 December 2020

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

1 reference

12 December 2020